The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma

Yamaguchi, Shigeru; Ishi, Yukitomo; Motegi, Hiroaki; Okamoto, Michinari; Kobayashi, Hiroyuki; Hirata, Kenji; Oda, Yoshitaka; Tanaka, Shinya; Terasaka, Shunsuke; Houkin, Kiyohiro

The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma

Yamaguchi, Shigeru; Ishi, Yukitomo; Motegi, Hiroaki et al.

Journal of Neurosurgical Sciences, 2020, 64(6), 502-508

Permalink : https://hdl.handle.net/2115/83410

このアイテムのアクセス数:751件（2026-08-07 21:12 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
J Neurosurg Sci 64 502-508	pdf	1.51 MB	535

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/83410
タイトル	The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma
著者	Yamaguchi, Shigeru ; Ishi, Yukitomo ; Motegi, Hiroaki ; Okamoto, Michinari ; Kobayashi, Hiroyuki ; Hirata, Kenji ; Oda, Yoshitaka ; Tanaka, Shinya ; Terasaka, Shunsuke ; Houkin, Kiyohiro
著者名 Yamaguchi, Shigeru
著者名 Ishi, Yukitomo
著者名 Motegi, Hiroaki
著者名 Okamoto, Michinari
著者名 Kobayashi, Hiroyuki
著者名 Hirata, Kenji
著者名 Oda, Yoshitaka
著者名 Tanaka, Shinya
著者名 Terasaka, Shunsuke
著者名 Houkin, Kiyohiro
言語	英語
キーワード	Astrocytoma
	Bevacizumab
	Glioblastoma
	Radiotherapy
	Temozolomide
発行日	2020-12
出版者	Edizioni Minerva Medica
収録物名	Journal of Neurosurgical Sciences
巻(号)	64(6)
ページ	502-508
抄録	BACKGROUND: Although newly diagnosed high-grade glioma patients in Japan can receive bevacizumab (BEV) as first-line chemotherapy. randomized clinical trials have not shown a survival benefit for BEV for these patients. In this study, we investigated whether selective add-on BEV for patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA) improves prognosis, in cases where tumors were continuously growing during radiotherapy concomitant with temozolomide (TMZ). METHODS: We conducted a retrospective survey of the overall survival (OS) of patients with GBM;AAs who were treated in our institution between 2006 and 2016. Patients whose tumors were continuously growing regardless of radiotherapy were categorized as the "progressive" group; remaining patients were categorized as the "non-progressive" group. Since 2013, patients in the "progressive" group received add-on BEV therapy with the Stupp regimen during or just after radiotherapy. RESULTS: Of 151 GBM/AA patients, 34 (22.5%) were categorized in the "progressive" group. Median OSs of the "progressive" and "nonprogressive" groups were 13.2 months and 25.3 months, respectively (P<0.001). Twelve patients in the "progressive" group received add-on BEV therapy, and their median OS was 20.2 months; whereas for the remaining 22 patients in the "progressive" group who were treated before the BEV era, their median OS was 10.5 months. In the "progressive" group, add-on BEV significantly extended OS (P 0.018) and was the lone clinical factor of better prognosis. CONCLUSIONS: We found that, for patients with GBM/AAs whose tumors were continuously growing during radiotherapy, add-on BEV treatment resulted in survival benefits.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	This is a postprint version of the article published in Journal of Neurosurgical Sciences. This version is free to view and download to private research and study only. Not for redistribution or re-use. ©Edizioni Minerva Medica. The final published article is available online on Minerva Medica website at https:doi.org 10.23736/S0390-5616.18.04463-6.
PISSN	0390-5616
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.23736/S0390-5616.18.04463-6